A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Trial Profile

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs RRx 001 (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
  • Indications Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms QUADRUPLE THREAT; TRIPLE THREAT
  • Sponsors EpicentRx
  • Most Recent Events

    • 05 Apr 2017 Results reporting comparison between expression patterns of TGF-beta1 and TGF-betaRI in patient-derived biopsy samples obtained at screening and post RRx-001 in QUADRUPLE THREAT phase II clinical trial, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 13 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.
    • 13 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top